Search | Clinical Trials Finder

Conditions: Early Stage Parkinson Disease
Interventions: Pardaprunox, pramipexole, Placebo Comparator; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 30 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: Birmingham, Alabama • Oceanside, California • Oxnard, California + 13 more

Conditions: Infection, Transplant;Failure,Kidney
Interventions: Mycophenolate Mofetil; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Achondroplasia
Interventions: Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration; Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 0 Years to 32 Months
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Oakland, California • Baltimore, Maryland • Madison, Wisconsin

Conditions: Urinary Tract Infections
Interventions: Cranberry juice, Placebo cranberry juice; Drug · Dietary Supplement
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Pain, Postoperative Pain Control
Interventions: Experimental: LTG-001 High Dose, Experimental: LTG-001 Low Dose, Active Comparator: HB/APAP, Placebo Comparator; Drug
Lead sponsor: Latigo Biotherapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Phoenix, Arizona • Atlanta, Georgia • Houston, Texas + 2 more

Conditions: Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
Interventions: PF- 00610355, Placebo, Salmeterol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 30
States / cities: Fairhope, Alabama • San Diego, California • Spring Valley, California + 22 more

Conditions: ANCA Associated Vasculitis (AAV)
Interventions: Rapcabtagene autoleucel, Active Comparator, Glucocorticoids; Biological · Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 11
States / cities: Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 8 more

Conditions: Premature Birth of Newborn, Enterocolitis, Necrotizing
Interventions: Ampicillin, Gentamicins, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: Up to 6 Hours
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rib Fractures
Interventions: Cryoneurolysis, Sham comparator; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: SARS-CoV-2
Interventions: SPIKEVAX; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: Not listed
Enrollment: 15,196,685 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19, Sars-CoV-2 Infection
Interventions: Sky Medical™ Rapid Antigen Test; Diagnostic Test
Lead sponsor: Sky Medical Supplies & Equipments, LLC; Industry
Eligibility: 7 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lake Worth, Florida

Conditions: Hereditary Inclusion Body Myopathy (HIBM)
Interventions: Sialic Acid Extended Release (SA-ER) Tablets, Sialic Acid Extended Release (SA-ER) Tables; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Costa Mesa, California • New York, New York

Conditions: OCD
Interventions: escitalopram, Placebo ( sugar pill); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypercholesterolemia
Interventions: Atorvastatin, AEGR-733; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 5
States / cities: Pinellas Park, Florida • Edina, Minnesota • Mogadore, Ohio + 2 more

Conditions: Friedreich Ataxia
Interventions: CTI-1601, Placebo; Biological · Other
Lead sponsor: Larimar Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Psoriatic Arthritis
Interventions: Secukinumab (75 mg), Secukinumab (150 mg), Placebo Comparator; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 20 more

Conditions: Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions: Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Placebo, tiotropium + Olodaterol, Tiotropium, Olodaterol, Respimat; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more

Conditions: Stroke, Pulmonary Ventilation, Exercise Therapy
Interventions: IMT with High Resistance EMT, IMT with Low Resistance EMT; Behavioral
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cystitis, Interstitial
Interventions: Certolizumab pegol, Placebo; Biological · Drug
Lead sponsor: ICStudy, LLC; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Escondido, California

Conditions: Major Depressive Disorder
Interventions: eCBT Mood; Behavioral
Lead sponsor: MindApps; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Leesburg, Florida • Orlando, Florida

Conditions: Gut Health, Bloating, Irregular Bowel Movements, Gastrointestinal Symptoms
Interventions: Active Supplement, Placebo Comparator; Dietary Supplement
Lead sponsor: Belli Welli Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Alpha 1-Antitrypsin Deficiency
Interventions: Fazisiran Injection, Placebo; Drug · Other
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more

Conditions: Breast Neoplasms
Interventions: Sunitinib malate, Taxotere; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 8
States / cities: Berkely, California • Shreveport, Louisiana • Beaumont, Texas + 5 more

Search by objective public record fields.

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

Cranberry Juice for Treatment of Urinary Tract Infections

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome

Intercostal Cryoneurolysis Following Traumatic Rib Fractures

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

This Trial is a Clinical Performance Validation Study That Will Evaluate the Clinical Agreement of the Sky Medical™ Rapid Antigen Test Comparing the Antigen Rapid Test to RT-PCR

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder

Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

Ventilatory Muscle Training in Stroke

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder

A Study to Evaluate the Effects of a Fiber Supplement on Gut Health

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer